Seres Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Seres Therapeutics, Inc. (MCRB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-12
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $1.81M, a 97.92% decline year-over-year.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $25.00K.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.05M, a 96.67% decline from fiscal 2022.
- Seres Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $91.41M, a 634.71% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.84M derived: sum of 2 quarters · filed 2026-03-12 | $3.05M derived: sum of 3 quarters · filed 2026-03-12 | $3.05M 10-K · filed 2026-03-12 |
| 2023-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.24M derived: sum of 2 quarters · filed 2024-11-13 | $1.24M 10-Q · filed 2024-11-13 | $88.28M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.21M 10-Q · filed 2024-08-13 | $88.25M derived: sum of 3 quarters · filed 2025-03-13 | $88.25M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $87.04M derived: sum of 2 quarters · filed 2025-03-13 | $87.04M derived: sum of 3 quarters · filed 2025-03-13 | $87.04M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $87.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $87.04M derived: sum of 2 quarters · filed 2025-03-13 | $87.04M derived: sum of 3 quarters · filed 2025-03-13 | $91.41M 10-K · filed 2025-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $4.37M 10-Q · filed 2023-11-02 | $11.97M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.37M 10-Q · filed 2023-08-08 | $11.97M derived: sum of 3 quarters · filed 2024-03-05 | $11.97M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $4.37M 10-Q · filed 2023-05-09 | $11.97M derived: sum of 2 quarters · filed 2024-03-05 | $11.97M derived: sum of 3 quarters · filed 2024-03-05 | $16.81M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $7.60M derived: sum of 2 quarters · filed 2024-03-05 | $12.44M derived: sum of 3 quarters · filed 2024-03-05 | $12.44M 10-K · filed 2024-03-05 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.84M derived: sum of 2 quarters · filed 2022-11-02 | $4.84M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $4.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $4.84M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-07 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $154.00K 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $154.00K 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |